CN101679425B - 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途 - Google Patents

6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途 Download PDF

Info

Publication number
CN101679425B
CN101679425B CN2008800197101A CN200880019710A CN101679425B CN 101679425 B CN101679425 B CN 101679425B CN 2008800197101 A CN2008800197101 A CN 2008800197101A CN 200880019710 A CN200880019710 A CN 200880019710A CN 101679425 B CN101679425 B CN 101679425B
Authority
CN
China
Prior art keywords
compound
compounds
tumour
purposes
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800197101A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679425A (zh
Inventor
D·多施
M·武赫雷尔
L·T·布格多夫
C·西伦贝格
C·埃斯达尔
T·J·J·穆勒
E·莫库尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN101679425A publication Critical patent/CN101679425A/zh
Application granted granted Critical
Publication of CN101679425B publication Critical patent/CN101679425B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800197101A 2007-06-21 2008-05-23 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途 Expired - Fee Related CN101679425B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007028515.0 2007-06-21
DE102007028515A DE102007028515A1 (de) 2007-06-21 2007-06-21 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
PCT/EP2008/004151 WO2008155000A1 (de) 2007-06-21 2008-05-23 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids

Publications (2)

Publication Number Publication Date
CN101679425A CN101679425A (zh) 2010-03-24
CN101679425B true CN101679425B (zh) 2013-11-06

Family

ID=39916277

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800197101A Expired - Fee Related CN101679425B (zh) 2007-06-21 2008-05-23 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途

Country Status (16)

Country Link
US (1) US8546390B2 (enExample)
EP (1) EP2155745B1 (enExample)
JP (1) JP5411849B2 (enExample)
KR (1) KR20100040862A (enExample)
CN (1) CN101679425B (enExample)
AR (1) AR067081A1 (enExample)
AU (1) AU2008266584B2 (enExample)
BR (1) BRPI0812944A2 (enExample)
CA (1) CA2691223C (enExample)
DE (1) DE102007028515A1 (enExample)
EA (1) EA016160B1 (enExample)
ES (1) ES2533873T3 (enExample)
IL (1) IL202828A0 (enExample)
MX (1) MX2009013341A (enExample)
WO (1) WO2008155000A1 (enExample)
ZA (1) ZA201000432B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078020A4 (en) * 2007-04-10 2011-10-19 Sgx Pharmaceuticals Inc HETEROCYCLIC MODULATORS WITH FUSED CYCLES FOR KINASES
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
DE102009060174A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
TWI498325B (zh) * 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
JP6325078B2 (ja) * 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017161004A1 (en) 2016-03-15 2017-09-21 University Of South Florida PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
CN113710668B (zh) * 2019-04-09 2025-01-07 Opna生物公司 用于ep300或cbp调节及其适应症的缩合吖嗪
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
CN118772140A (zh) * 2023-04-07 2024-10-15 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095400A1 (en) * 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7361763B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095400A1 (en) * 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRESNEDA ETAL.Synthesis of the indole alkaloids meridianins from the tunicate aplidium meridianum.《tetrahedron》.2001,第57卷(第2001期),2355-2363. *

Also Published As

Publication number Publication date
JP5411849B2 (ja) 2014-02-12
KR20100040862A (ko) 2010-04-21
US8546390B2 (en) 2013-10-01
ZA201000432B (en) 2010-10-27
BRPI0812944A2 (pt) 2014-12-16
EA201000004A1 (ru) 2010-06-30
EP2155745B1 (de) 2015-01-28
JP2010530376A (ja) 2010-09-09
WO2008155000A1 (de) 2008-12-24
AU2008266584B2 (en) 2013-04-04
CA2691223C (en) 2015-12-01
AU2008266584A1 (en) 2008-12-24
CA2691223A1 (en) 2008-12-24
ES2533873T3 (es) 2015-04-15
EP2155745A1 (de) 2010-02-24
DE102007028515A1 (de) 2008-12-24
US20110082140A1 (en) 2011-04-07
IL202828A0 (en) 2010-06-30
MX2009013341A (es) 2010-01-18
AR067081A1 (es) 2009-09-30
CN101679425A (zh) 2010-03-24
EA016160B1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
CN101679425B (zh) 6-(吡咯并吡啶基)嘧啶-2-基胺及其治疗癌症和艾滋病的用途
JP5587874B2 (ja) ピロロピリジニルピリミジン−２−イルアミン誘導体
CN103502247B (zh) 7-氮杂吲哚衍生物
ES2436445T3 (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina
JP5891233B2 (ja) ７−（［１，２，３］トリアゾール−４−イル）−ピロロ［２，３−ｂ］ピラジン誘導体
JP5524864B2 (ja) ４−（ピロロ［２，３−ｃ］ピリジン−３−イル）ピリミジン−２−アミン誘導体
CN103403005B (zh) 5-([1,2,3]-三唑-4-基)-7H-吡咯并[2,3-d]嘧啶衍生物
CN102666544B (zh) 吡咯并[2,3-d]吡嗪-7-基嘧啶化合物
JP2013544264A (ja) ＰＤＫ１阻害剤としての３−ヘタリール置換ピロロ［２，３−ｂ］ピリジン誘導体
CN101616918A (zh) 4-(吡咯并吡啶基)嘧啶-2-基胺衍生物
CN103764651B (zh) 适合治疗癌症疾病的7-氮杂吲哚衍生物
HK1142332A (en) 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids
HK1140203A (en) 4-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives
HK1157766A (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
HK1169118A (en) 3-([1,2,3]triazol-4-yl)-pyrrolo[2,3-b]pyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142332

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1142332

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131106

CF01 Termination of patent right due to non-payment of annual fee